Moloney Securities Asset Management, LLC Genmab A/S Transaction History

Moloney Securities Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$27.94 - $35.44 $338,074 - $428,824	-12,100 Reduced 53.29%	10,604 $337,000
Q3 2023 Oct 31, 2023	SELL	$35.27 - $42.24 $264,525 - $316,800	-7,500 Reduced 24.83%	22,704 $800,000
Q2 2023 Jul 31, 2023	BUY	$37.4 - $42.94 $1.13 Million - $1.3 Million	30,204 New	30,204 $1.15 Million
Q4 2021 Jan 28, 2022	SELL	$35.87 - $47.12 $169,880 - $223,160	-4,736 Closed	0 $0
Q3 2021 Oct 27, 2021	SELL	$41.55 - $48.72 $17,617 - $20,657	-424 Reduced 8.22%	4,736 $207,000
Q2 2021 Jul 26, 2021	BUY	$32.88 - $44.57 $169,660 - $229,981	5,160 New	5,160 $211,000
Q3 2020 Oct 20, 2020	SELL	$33.07 - $38.68 $1.32 Million - $1.54 Million	-39,900 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$20.05 - $33.89 $604,507 - $1.02 Million	30,150 Added 309.23%	39,900 $1.35 Million
Q1 2020 May 08, 2020	SELL	$17.15 - $25.22 $25,724 - $37,830	-1,500 Reduced 13.33%	9,750 $207,000
Q4 2019 Feb 06, 2020	SELL	$18.88 - $24.14 $9,440 - $12,070	-500 Reduced 4.26%	11,250 $251,000
Q3 2019 Nov 01, 2019	BUY	$18.0 - $21.38 $211,500 - $251,215	11,750 New	11,750 $238,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Moloney Securities Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Moloney Securities Asset Management, LLC with notifications on news.